Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 1, 2010, Pages 192-201

  Bartusik, Dorota ^a,b   Tomanek, Boguslaw ^a,b,c,d   Lattová, Erika ^e   Perreault, Hélène ^e   Fallone, Gino ^b,d  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c INSTITUTE OF NUCLEAR PHYSICS   (Poland)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Immunotargeting; MALDI MS; MCF 7 breast cancer cells; MRI; Three dimensional cell culture

Indexed keywords

CATION; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; HERMES ANTIGEN; HYALURONIC ACID; LIPID; LIPOFECTAMINE; LIPOPLEX; LYMPHOCYTE RECEPTOR; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PLASMID DNA; PROTEIN ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CANCER MORTALITY; CANCER RESISTANCE; CANCER THERAPY; CELL AGGREGATION; CELL STRAIN MCF 7; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOLLOW FIBER REACTOR; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; HYALURONIC ACID; LIPIDS; MAGNETIC RESONANCE IMAGING; PLASMIDS; RECEPTOR, ERBB-2; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 70349336682     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.07.032     Document Type: Article

References (31)

1. Mackey J., McLeod D., Ragaz J., Gelmon K., Verma S., Pritchard K., Laing K., Provencher L., and Charbonneau L.F. Adjuvant targeted therapy in early breast cancer. Cancer 115 (2009) 1154-1168
2. Götte M., and Yip G.W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 66 (2006) 10233-10237
3. Kincade P.W., Zheng Z., Katoh S., and Hanson L. The importance of cellular environment to function of the CD44 matrix receptor. Curr. Opin. Cell Biol. 9 (1997) 635-642
4. Nielsen D.L., Andersson M., and Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat. Rev. 35 (2009) 121-136
5. DeGrendele H.C., Estess P., Picker L.J., and Siegelman M.H. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte/endothelial cell primary adhesion pathway. J. Exp. Med. 183 (1996) 1119-1130
6. Hudziak R.M., Schlessinger J., and Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7159-7163
7. Antonova I., Arancio O., Trillat A.C., Wang H.G., Zablow L., Udo H., Kandel E.R., and Hawkins R.D. Rapid increase in clusters of presynaptic proteins at onset of long-lasting potentiation. Science 294 (2001) 1547-1550
8. Huang S., and Ingber D. Cell tension matrix mechanics and cancer development. Cancer Cell 8 (2005) 175-176
9. Ouhtit A., Abd Elmageed Z.Y., Abdraboh M.E., Lioe T.F., and Raj M.H. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am. J. Pathol. 171 (2007) 2033-2039
10. Mahato R.I., Henry J., Naragan A.S., Sabek O., Fraga D., Kotb M., and Gaber A.O. Cationic lipid polymer-based gene delivery to human pancreatic islets. Mol. Ther. 7 (2003) 89-100
11. Zuhorn I.S., and Hoekstra D. On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question?. J. Membr. Biol. 189 (2002) 167-179
12. Draffin J.E., McFarlane S., Hill A., Johnston P.G., and Waugh D.J.J. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res. 64 (2004) 5702-5711
13. Liao H.X., Lee D.M., Levesque M.C., and Haynes B.F. N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. J. Immunol. 155 (1995) 3938-3945
14. Griffith L.G., and Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 7 (2006) 211-224
15. Cukierman E., Pankov R., Stevens D.R., and Yamanda K.M. Taking cell-matrix adhesions to the third dimension. Science 294 (2001) 1708-1712
16. Kono K., Rongcun Y., and Charo J. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer 78 (1998) 202-208
17. Ibrahim E.M., Stewart R.L., Corke K., Blackett A.D., Tidy J.A., and Wells M. Upregulation of CD44 expression by interleukins 1, 4 and 13, transforming growth factor-beta1, estrogen, and progestogen in human cervical adenocarcinoma cell lines. Int. J. Gynecol. Cancer 16 (2006) 1631-1642
18. Takahashi K., and Loo G. Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. Biochem. Pharmacol. 67 (2004) 315-324
19. Xu L., Frederik P., Pirollo K.F., Tang W.H., Rait A., Xiang L.M., Huang W., Cruz I., Yin Y., and Chang E.H. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum. Gene Ther. 13 (2002) 469-481
20. Mao Q., and Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 7 (2005) E118-E133
21. Lattová E., Kapková P., Krokhin O., and Perreault H. Method for investigation of oligosaccharides from glycopeptides: direct determination of glycosylation sites in proteins. Anal. Chem. 78 (2006) 2977-2984
22. Lattová E., Varma S., Bezabeh T., and Perreault H. Matrix-assisted laser desorption/ionization on-target method for the investigation of oligosaccharides and glycosylation sites in glycopeptides and glycoproteins. Rapid Commun. Mass Spectrom. 21 (2007) 1644-1650
23. Jemal A., Siegel R., and Ward E. Cancer statistics 2006. Cancer J. Clin. 56 (2006) 106-130
24. Kauraniemi P., Hautaniemi S., Autio R., Astola J., Monni O., Elkahloun A., and Kallioniemi A. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 23 (2004) 1010-1013
25. Colbern G.T., Hiller A.J., Musterer R.S., Working P.K., and Henderson I.C. Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model. J. Inorg. Biochem. 77 (1999) 117-120
26. Freemantle C., Alam C.A., Brown J.R., Seed M.P., and Willoughby D.A. The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX-0001). Int. J. Tissue React. 17 (1995) 157-166
27. Shuster S., Frost G.I., Csoka A.B., Formby B., and Stern R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int. J. Cancer 102 (2002) 192-197
28. Bourguignon L.Y., Zhu H., Zhou B., Diedrich F., Singleton P.A., and Hung M.C. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J. Biol. Chem. 276 (2001) 48679-48692
29. Lokeshwar V.B., Cerwinka W.H., Isoyama T., and Lokeshwar B.L. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res. 65 (2005) 7782-7789
30. Eliaz R.E., Nir S., and Szoka Jr. F.C. Interactions of hyaluronan-targeted liposomes with cultured cells: modeling of binding and endocytosis. Methods Enzymol. 387 (2004) 16-33
31. Jena A., Oberoi R., Rawal S., Das S.K., and Pandey K. Parametrical invasion in carcinoma of cervix: role of MRI measured tumour volume. Br. J. Radiol. 78 (2005) 1075-1077